



**PATIENT INFORMATION** (use sticker if available)

Last name \_\_\_\_\_

First name(s) \_\_\_\_\_

Date of birth \_\_\_\_\_

Address \_\_\_\_\_  
\_\_\_\_\_

female                       male

Ethnic background \_\_\_\_\_  
(may be important in recessive conditions)

**Institute of Human Genetics  
University Hospital of Cologne  
Kerpener Str. 34  
50931 Cologne  
Germany**

Phone +49/221/478-86811, Fax +49/221/478-86812  
www.uk-koeln.de/humangenetik

**Billing**

Test will be paid by     referring facility     patient

*Please note that international requests must be accompanied  
by a confirmation of payment. Please contact us for details.*

**Request for molecular genetic testing**

See page 2 for available tests

**Reason for testing:**

Please provide pedigree / clinical findings / details on pregnancy (week), previous genetic tests performed, if appropriate.

**Informed consent form for genetic testing (“DNA analysis”)**

*According to the German Genetic Diagnostics Act (www.bvdh.de/newsdownload/40/Gesetzblatt\_GenDG\_BGBL04082009.pdf)*

- 1.) I herewith consent that genetic testing will be performed on a blood/biological sample derived from  
 me     my child     the person under my legal guardianship  
 I have received full information from my physician concerning the suspected diagnosis of

\_\_\_\_\_ ,  
its genetic basis and the possible interpretations and limitations of the diagnostic testing.

- 2.) I herewith consent that the genetic test results will not be destroyed after 10 years as laid down in German statutory provisions but will be retained so that they will be available to me and/or members of my family.
- 3.) I herewith consent that the test results will be stored in hard copy and as electronic files in accordance with legal provisions and that they will be used without disclosing personal data (i.e. in pseudonymized form) for scientific or quality management purposes.
- 4.) I herewith consent that, after the requested testing has been completed, the Institute of Human Genetics, University Hospital of Cologne, may use the remaining sample material without disclosing personal data (i.e. in pseudonymized form) for quality management, teaching and/or scientific purposes.
- 5.) Results of the above stated genetic testing may be disclosed to the following attending physician(s):

\_\_\_\_\_

– Please delete as appropriate –

*I am free to withdraw any of the above statements in writing without giving any reasons.  
Such withdrawal will involve no loss of benefits for me.*

**Referring physician**

Signature \_\_\_\_\_ Place, Date \_\_\_\_\_

Name \_\_\_\_\_

Institution \_\_\_\_\_  
\_\_\_\_\_

Phone, Fax \_\_\_\_\_

**Patient/legal guardian**

Signature \_\_\_\_\_ Place, Date \_\_\_\_\_

Name \_\_\_\_\_

Address \_\_\_\_\_  
\_\_\_\_\_

Phone \_\_\_\_\_

## Molecular genetic request form

### NEUROMUSCULAR DISORDERS (Contact: brunhilde.wirth@uk-koeln.de, nadine.plume@uk-koeln.de, jutta.becker@uk-koeln.de, raoul.heller@uk-koeln.de)

- |  |  |   |
|--|--|---|
| <p><b>Spinal muscular atrophy type I-IV (SMA); recessive</b></p> <p><input type="checkbox"/> SMN1 deletion test (MLPA)</p> <p><input type="checkbox"/> SMN1 carrier test (MLPA)</p> <p><input type="checkbox"/> SMN1 point mutation analysis (sequencing) (upon inquiry)</p> <p><input type="checkbox"/> SMN2 (MLPA)</p> | <p><b>X-linked SMA; X-recessive</b></p> <p><input type="checkbox"/> UBA1 (sequencing)</p>  | <p><b>Amyotrophic lateral sclerosis (ALS); familial</b></p> <p><input type="checkbox"/> SOD1 (sequencing)</p> <p><input type="checkbox"/> ALS2 (sequencing)</p> <p><input type="checkbox"/> VAPB (sequencing)</p>                 |
| <p><b>Spinal muscular atrophy with respiratory distress type 1 (SMARD1), diaphragmatic SMA (DSMA1); recessive</b></p> <p><input type="checkbox"/> IGHMBP2 (sequencing)</p>   | <p><b>Charcot-Marie-Tooth 2C (HMSN IIc), scapuloperoneal SMA, distal benign SMA with contractures; dominant</b></p> <p><input type="checkbox"/> TRPV4 (sequencing)</p>   |   |
| <p><b>Arthrogryposis (AMC), distal (DA1, DA2A, DA2B, DA7); dominant</b></p> <p><input type="checkbox"/> TPM2 (sequencing)</p> <p><input type="checkbox"/> TNNI2 (sequencing)</p> <p><input type="checkbox"/> TNNT3 (sequencing)</p>  | <p><b>Fetal akinesia deformation sequence (FADS), Pena-Shokeir; recessive</b></p> <p><input type="checkbox"/> RAPSN (sequencing)</p> <p><input type="checkbox"/> CHRNG (sequencing)</p> <p><input type="checkbox"/> other (upon inquiry)</p> | <p><b>Congenital myopathy (fiber-type disproportion); dominant</b></p> <p><input type="checkbox"/> ACTA1 (sequencing)</p> <p><input type="checkbox"/> SEPN1 (sequencing)</p> <p><input type="checkbox"/> other (upon inquiry)</p> |
| <p><b>Pontocerebellar hypoplasia (PCH 2 and 4); recessive</b></p> <p><input type="checkbox"/> TSEN54 (sequencing)</p> <p><input type="checkbox"/> TSEN2 (sequencing)</p> <p><input type="checkbox"/> TSEN34 (sequencing)</p> <p><input type="checkbox"/> other (upon inquiry)</p>  |  |   |

### SKELETAL DISORDERS (Contact: christian.netzer@uk-koeln.de, lutz.garbes@uk-koeln.de, jutta.becker@uk-koeln.de)

- |  |   |
|--|---|
| <p><b>Osteogenesis imperfecta (OI) type I – IV; dominant</b></p> <p><input type="checkbox"/> COL1A1 (sequencing, MLPA)</p> <p><input type="checkbox"/> COL1A2 (sequencing, MLPA)</p> | <p><b>Osteogenesis imperfecta (OI) type IIB und VII; recessive</b></p> <p><input type="checkbox"/> CRTAP (sequencing)</p> <p><input type="checkbox"/> FKBP10 (sequencing)</p> <p><input type="checkbox"/> LEPRE1 (sequencing)</p> |
|  | <p><input type="checkbox"/> PPIB (sequencing)</p> <p><input type="checkbox"/> SP7 (sequencing)</p>  |
|  | <p><input type="checkbox"/> SERPINH1 (sequencing)</p> <p><input type="checkbox"/> SERPINF1 (sequencing)</p>   |

### KIDNEY DISORDERS (Contact: bodo.beck@uk-koeln.de, nadine.plume@uk-koeln.de)

- |  |   |   |
|--|---|---|
| <p><b>Primary hyperoxaluria type 1 (PH I); recessive</b></p> <p><input type="checkbox"/> AGXT (sequencing, MLPA)</p>   | <p><b>Primary hyperoxaluria type 2 (PH II); recessive</b></p> <p><input type="checkbox"/> GRHPR (sequencing, MLPA)</p>  | <p><b>Primary hyperoxaluria type 3 (PH III); recessive</b></p> <p><input type="checkbox"/> DHAPSL (sequencing)</p>  |
| <p><b>Nephrotic syndrome; recessive</b></p> <p><input type="checkbox"/> NPHS1 (sequencing)</p> <p><input type="checkbox"/> NPHS2 (sequencing)</p> <p><input type="checkbox"/> WT1 (sequencing)</p> | <p><b>Medullary cystic kidney disease (MCKD)/ Urinary tract malformations; dominant</b></p> <p><input type="checkbox"/> UMOD (sequencing)</p> <p><input type="checkbox"/> HNF1β (sequencing, MLPA)</p> <p><input type="checkbox"/> REN (sequencing)</p> | <p><b>Renal-tubular dysgenesis (RTD); recessive</b></p> <p><input type="checkbox"/> ACE (sequencing)</p> <p><input type="checkbox"/> AGT (sequencing)</p> <p><input type="checkbox"/> AGTR2 (sequencing)</p> <p><input type="checkbox"/> REN (sequencing)</p> |

### KABUKI SYNDROME (Contact: bwołnik@uni-koeln.de, jutta.becker@uk-koeln.de)

- MLL2 (sequencing)

### CRANIOFACIAL MALFORMATION SYNDROMES (Contact: bwołnik@uni-koeln.de, jutta.becker@uk-koeln.de)

- |   |   |
|---|---|
| <p><b>Syndromic craniosynostoses; dominant (incl. Alpert, Pfeiffer, Couzon, Saethre-Chotzen, Muenke syndromes)</b></p> <p><input type="checkbox"/> FGFR1 (sequencing, hot spots)</p> <p><input type="checkbox"/> FGFR2 (sequencing, hot spots)</p> <p><input type="checkbox"/> FGFR3 (sequencing, hot spots)</p> <p><input type="checkbox"/> TWIST (sequencing, MLPA)</p> | <p><b>LADD syndrome, ALSG syndrome; dominant</b></p> <p><input type="checkbox"/> FGF10 (sequencing, MLPA)</p> <p><input type="checkbox"/> FGFR2 (sequencing, TK domain)</p> <p><input type="checkbox"/> FGFR3 (sequencing, TK domain)</p> |
|---|---|

### HEARING DISORDERS (Contact: christian.netzer@uk-koeln.de, jutta.becker@uk-koeln.de)

- |  |  |
|--|--|
| <p><b>Autosomal recessive/digenic hearing loss</b></p> <p><input type="checkbox"/> GJB2 (Cx 26) (sequencing)</p> <p><input type="checkbox"/> GJB6 (Cx 30) (PCR of junction fragment)</p> | <p><b>Pendred syndrome/DFNB4; recessive</b></p> <p><input type="checkbox"/> SLC26A4 (sequencing)</p> |
|--|--|

### MULTISYSTEM DISORDERS (Contact: christian.netzer@uk-koeln.de, lutz.garbes@uk-koeln.de, jutta.becker@uk-koeln.de)

- Cystic fibrosis; recessive**
- CFTR (hot spots, OLA)
- CFTR (sequencing)
- CFTR (sequencing, MLPA)

### Sample and shipping requirements

5-10 ml EDTA blood / ≥10 ml amniotic fluid / chorionic villi / ≥500 ng DNA;  
1-2 ml EDTA blood acceptable for newborns and infants (please contact us).

**Please contact us before submitting samples for prenatal diagnosis/during pregnancy.**

Ship samples at room temperature. Please make sure that samples are correctly labelled (name & dob)!

Testing will only be performed if samples are accompanied by a completed and signed informed consent form (s. page 1).